YD Bio Limited

10/31/2026

2027 is coming — and we’re stepping into it together. 🕶️✨

A huge thank you to the EG BioMed team for including us in this one. Here’s to the people behind the science — and everything we’ll build together in the year ahead.

To our teams on both sides: thank you for everything this year. See you in 2027. 🙌

🎬 Watch the video: https://youtube.com/shorts/cwkZnG6Rz1Y?is=rSmGGDv6-4V2upRE

#2027

A big thank you to our team for a year of hard work and dedication!...

10/31/2026

2027 is coming — and we’re stepping into it together. 🕶️✨

A huge thank you to the EG BioMed team for including us in this one. Here’s to the people behind the science — and everything we’ll build together in the year ahead.

To our teams on both sides: thank you for everything this year. See you in 2027. 🙌

🎬 Watch the video👇

#2027

10/23/2026

What does YD Bio actually do?
We’re a Nasdaq-listed biotech building an integrated healthcare platform across five business lines.

🔬 Cancer Detection | OkaiDx™ DNA methylation blood tests; CLIA/CAP-certified lab; 47 U.S. states; physician-ordered
👁 Ocular Products | Exovisse™ (FDA 510(k)), available nationwide
🧬 Ocular Therapeutics | LSC exosome therapy in development; DMF filed with FDA
📋 Regulatory Services | U.S. FDA agent for Asian pharma clients
🌿 Consumer Health | Physician-partnered nutraceuticals launched Taiwan, Aug 2026

This is what building a healthcare platform looks like.

🔗 ir.ydesgroup.com

10/21/2026

We’re excited to announce a new strategic partnership with EG BioMed and JoiiUp — bringing AI-powered cancer risk assessment directly into corporate wellness programs.

Together, we’ve integrated the AI Cancer Risk Assessment into JoiiUp’s JoiiSports app — a platform already trusted by over 400 companies and backed by 12+ years of workplace health experience.

What makes this different:
✅ Validated using 1,200+ clinical records in collaboration with 3 TMU-affiliated hospitals
✅ Covers 10 cancer types through an online questionnaire — no blood draws, no imaging
✅ Delivers personalized risk reports and lifestyle recommendations via SSO directly in the JoiiSports app

This is the first step in building a comprehensive cancer management pathway — from awareness to early action.

This tool provides personalized health guidance for reference purposes only. It is not intended for cancer diagnosis — we encourage users to discuss results with a qualified healthcare professional.

Learn more → https://pse.is/9s2xe3

10/16/2026

”I'm too young to worry about this."

That might be one of the most common misconceptions about breast cancer.

According to the American Cancer Society, about 1 in 10 breast cancer diagnoses occur in women under 45. And the cancers that develop in younger women tend to be more aggressive — with higher rates of triple-negative and HER2-positive subtypes, and generally worse outcomes.

What's more, incidence rates in women under 50 are rising at 1.4% per year — faster than the overall average.

Contributing factors may include having fewer children, having a first child after 30, and excess body weight. But perhaps the biggest issue is simpler: younger women are less likely to get screened regularly, and more likely to brush off early symptoms — which means diagnoses often come later.

Age is not a shield. 🎗️

10/13/2026

🎗️ October 13 — Metastatic Breast Cancer Awareness Day

Let's not forget the patients living with cancer that has spread — facing their diagnosis with everything they have.

For them, treatment often focuses on extending life, controlling disease progression, and maintaining quality of life, making ongoing post-treatment follow-up and recurrence monitoring especially important. The OkaiDx™ Breast Cancer Monitoring blood test is offered by YD Bio together with its affiliate EG BioMed, through EG BioMed's CLIA/CAP-certified U.S. laboratory, analyzing cfDNA methylation to help track post-treatment changes.

Today, let's see them, and stand with them.



*For screening and risk-assessment purposes only. Not a diagnostic device.

10/12/2026

Every October, progress in breast cancer research deserves attention.

Cell-free DNA (cfDNA) methylation analysis — it sounds technical, but the idea behind it is surprisingly intuitive.

When cells break down, they release small DNA fragments into the bloodstream. These fragments carry chemical markers called methylation patterns — a kind of molecular fingerprint. By analyzing these patterns, researchers can observe cancer-associated molecular changes in the blood without invasive tissue sampling.

In breast cancer, studying how these molecular markers shift after treatment is an active area of translational research. EG BioMed — an affiliate of YD Bio Limited (Nasdaq: YDES) — supports research in this space through its CLIA/CAP-certified U.S. laboratory, using the OkaiDx™ platform.

10/08/2026

We've launched the AI Cancer Risk Assessment together with our affiliate EG BioMed — now available in English and Chinese.

🔹 10 minutes. 52 questions. A personalized risk report across 10 cancer types:
🔹 Breast · Colorectal · Lung · Head & Neck · Pancreatic
🔹 Liver · Endometrial · Prostate · Biliary Tract · Gastric

No blood draw. No imaging. No clinic visit required.

"Early awareness is the first step toward better outcomes. This tool is designed to lower the barrier to proactive health engagement — making it easier for individuals to understand their personal risk profile and take informed action." — Dr. Ethan Shen, Chairman and CEO, YD Bio

Available now at a promotional price of $10 USD. This tool is an educational awareness resource and is not a substitute for clinical diagnosis or medical advice.

🔗 Try it now: mdi.eg-bio.com

10/04/2026

💗 October is Breast Cancer Awareness Month

Breast cancer is one of the most common cancers among women — and early detection through regular screening remains our strongest first line of defense.

Beyond screening, long-term monitoring after treatment matters too. OkaiDx™ is offered by YD Bio (Nasdaq: YDES) together with its affiliate EG BioMed, through EG BioMed’s CLIA/CAP-certified laboratory in the U.S., researching cfDNA methylation for post-treatment breast cancer monitoring — currently for research use only (RUO), not yet FDA-cleared, and not for clinical diagnosis.

This month, take a moment to remind yourself — or someone you love — it might be time for a screening. 🩷

09/30/2026

More than half of pancreatic cancer patients are diagnosed at Stage IV.

According to NCI SEER data, the 5-year survival rate for Stage I pancreatic cancer is over 90%. By Stage IV, it drops below 5%. Same disease — nearly a 20x difference, based almost entirely on when it's caught.

Part of what makes pancreatic cancer so difficult is that early-stage disease rarely causes symptoms. Most patients don't seek care until something feels wrong — and by then, the window for effective treatment has often already closed.

OkaiDx™ analyzes cfDNA methylation from a single blood draw to detect early cancer signals, with the goal of opening that window before symptoms appear. Currently available through EG BioMed's CLIA/CAP-certified laboratory as a physician-authorized LDT.

Getting there earlier is possible.